Abstract PO-028: Clinical and genomic correlates of intratumoral HPV for oropharyngeal and cervical cancers
Authors: Yilmaz Emrullah , Miller Jacob A. , Koyfman Shlomo A. , Geiger Jessica L. , Silver Natalie , McGrail Daniel 
Published: September 2023

Introduction: p16 immunohistochemistry (IHC) is the most commonly used test for diagnosing Human Papillomavirus (HPV) related oropharyngeal cancers. HPV DNA or RNA tests have been used increasingly more recently. However, the significance of the intratumoral HPV expression levels is not established yet. Here, we analyzed the intratumoral HPV expression levels using The Cancer Genome Atlas (TCGA) database. Methods: HPV levels were analyzed for oropharyngeal and cervical cancers using the TCGA database at cBioPortal.1,2 Alphapapilloma virus genus was included in the analysis to capture all high-risk HPV types. The association of HPV levels with genomic and clinical features was assessed using either a Spearman correlation coefficient (continuous variables) or a rank-sum test (categorical variables). Results: In oropharyngeal cancer patients, the genomic analysis revealed that CYLD-mutated HPV-positive tumors had significantly higher HPV levels (p=0.0162). There was no difference in virus levels depending on PIK3CA mutation (p=0.370). Gene expression analysis showed a significant correlation of virus levels with MAP3K7 (TAK1) expression (r=0.37, p&lt;0.01). There was no difference in clinical features or survival depending on HPV levels. There was no significant difference among the common oncogenic mutations depending on HPV levels in cervical cancer patients. However, patients with low virus levels had shorter overall survival (PS) and disease-specific survival (DSS) (p=0.01 and 0.027, respectively). Patients with adenocarcinoma had higher levels of the virus when compared to squamous cell carcinoma. Discussion: Our study showed that intratumoral HPV level was correlated with CYLD mutations and TAK1 expression in oropharyngeal cancer patients. CYLD mutations are common in HPV-related head&neck cancers, occurring in up to 20% of tumors. CYLD is known to negatively regulate the NF-κB pathway by inactivating TAK1 and IKK complexes.3 Clinical outcomes were not different depending on the HPV levels in patients with oropharyngeal cancers in our study; however, there were a small number of patients in this study (n=48). Another HPV-related cancer, cervical cancer, was more commonly represented in the TCGA database (n=297). The patients with low HPV levels had poor prognosis in this larger cohort. HPV-directed therapies are emerging for HPV-related cancers. Understanding the role of the intratumoral HPV levels can help to improve viral targeted therapies. References: Cerami et al. The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data. Cancer Discovery. May 2012 2; 401. Gao et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013). Cui et al. CYLD Alterations in the Tumorigenesis and Progression of Human Papillomavirus-Associated Head and Neck Cancers. Mol Cancer Res. 2021 Jan;19(1):14-24.

Citation Format: Emrullah Yilmaz, Jacob A. Miller, Shlomo A. Koyfman, Jessica L. Geiger, Natalie Silver, Daniel McGrail. Clinical and genomic correlates of intratumoral HPV for oropharyngeal and cervical cancers [abstract]. In: Proceedings of the AACR-AHNS Head and Neck Cancer Conference: Innovating through Basic, Clinical, and Translational Research; 2023 Jul 7-8; Montreal, QC, Canada. Philadelphia (PA): AACR; Clin Cancer Res 2023;29(18_Suppl):Abstract nr PO-028.